Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

WHEN a migraine hits, most of us make a beeline for a dark room and hope the painkillers kick in fast. But what if popping ...

While migraine sufferers might try more traditional methods like using pain killers, the fast food chain's menu items can be ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Childhood migraines are on the rise, raising concerns among doctors. Hyderabad-based neurologist Dr. Sudhir Kumar notes cases ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

And once she became a mom, her migraine attacks made it tough to spend time with her kids. “It would take me out of the game, ...

Patients with acute episodic migraine consistently prioritize pain relief over other treatment attributes such as route of administration, adverse outcomes, and costs, according to study results ...

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has ...

Sensitivity to smell (osmophobia) or smelling things that aren't there (phantosmia) can be another symptom of migraine. An ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...